沃特世完成与碧迪业务合并，股价下跌近16%

Core Viewpoint - Waters Corporation has completed the merger with BD's biosciences and diagnostic solutions business, resulting in the establishment of four business divisions. However, the stock price has seen a significant decline post-merger [1]. Stock Performance - The stock price has dropped by 14.94% over the past week, reaching a low of $305.35 on February 12, marking a 60-day low. A slight rebound occurred on February 13, with the price rising to $324.32, an increase of 1.40% [3]. - Trading activity increased post-merger, with an average daily trading volume of approximately $1.14 billion from February 9 to 11, and a single-day trading volume of $1.219 billion on February 10, reflecting heightened market volatility [3]. Financial Report Analysis - The financial report for fiscal year 2025, released on February 12, shows total revenue of $3.165 billion, a year-on-year increase of 6.99%, with a slight net profit increase of 0.75%. However, Q4 revenue was $932 million, with a year-on-year net profit decline of 2.67% [4]. - The gross margin for the year was 57.77%, with operating cash flow of $653 million. Growth was driven by the pharmaceutical business, particularly in the Chinese market, which saw over 20% growth, and emerging products like PFAS testing and GLP-1 related revenues. However, short-term integration costs may pressure profit margins [4]. Institutional Perspectives - Following the merger, several institutions have updated their target prices, ranging from $350 to $440. Citigroup and Barclays have upgraded to "Buy," while Bank of America has lowered its target price to $350, maintaining a "Hold" rating, indicating market divergence regarding integration outcomes and growth trajectories [5].